Anticoagulants oraux directs et grossesse

CRAT, Etat des connaissances sur les AVK : warfarine, acénocoumarol, fluindione. http://www.lecrat.fr/articlePrint.php?id_article=695 (accessed 19 janvier 2021). Salem, 2014, Pharmacologie des anti-Xa et mécanismes d’action, Arch Cardiovasc Dis Suppl, 6, 79 Pharmacomédicale.org, Anticoagulants oraux directs (AODS) https://pharmacomedicale.org/medicaments/par-specialites/item/anticoagulants-oraux-directs-aods (accessed 19 janvier 2021). Bouget, 2020, Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study, Br J Clin Pharmacol, 86, 2519, 10.1111/bcp.14362 Ansm 2019, Anticoagulants Oraux Directs (AODs) (apixaban (Eliquis®), rivaroxaban (Xarelto®), dabigatran (Pradaxa®) et edoxaban (Lixiana®/Roteas®) non recommandés chez les patients présentant un Syndrome des Antiphospholipides (SAPL) - Lettre aux professionnels de santé. https://www.ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Anticoagulants-Oraux-Directs-AODs-apixaban-Eliquis-R-rivaroxaban-Xarelto-R-dabigatran-Pradaxa-R-et-edoxaban-Lixiana-R-Roteas-R-non-recommandes-chez-les-patients-presentant-un-Syndrome-des-Antiphospholipides-SAPL-Lettre-aux-professionnels-de-sante (accessed 19 janvier 2021). Tektonidou, 2019, EULAR recommendations for the management of antiphospholipid syndrome in adults, Ann Rheum Dis, 78, 1296, 10.1136/annrheumdis-2019-215213 Hoeltzenbein, 2016, Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre, Clin Res Cardiol, 105, 117, 10.1007/s00392-015-0893-5 Paulus, 2020, Is the use of direct oral anticoagulants safe during pregnancy? [Abstract], Reprod Toxicol, 97, 9, 10.1016/j.reprotox.2020.04.013 Beyer-Westendorf, 2020, Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study, Lancet Haematol, 7, e884, 10.1016/S2352-3026(20)30327-6 Bapat, 2014, Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta, Obstet Gynecol, 123, 1256, 10.1097/AOG.0000000000000277 Bapat, 2015, Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am J Obstet Gynecol, 213, [710.e1-6], 10.1016/j.ajog.2015.06.065 Bapat, 2016, Examining the transplacental passage of apixaban using the dually perfused human placenta, J Thromb Haemost, 14, 1436, 10.1111/jth.13353 Königsbrügge, 2014, Oral anticoagulation with rivaroxaban during pregnancy: a case report, Thromb Haemost, 112, 1323, 10.1160/th14-04-0393 Myers, 2016, Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): a warning, Obstet Med., 9, 40, 10.1177/1753495X15621814 Komori, 2020, Apixaban therapy in a pregnant woman with heparin-induced thrombocytopenia and venous thromboembolic events caused by congenital antithrombin deficiency: A case report, Case Rep Womens Health, 27, e00200, 10.1016/j.crwh.2020.e00200 CRAT, Héparines (HBPM et HNF) – Grossesse et allaitement. http://www.lecrat.fr/articlePrint.php?id_article=938 (accessed 19 janvier 2021). Kustos, 2019, Direct-acting oral anticoagulants and their reversal agents-an update, Medicines (Basel), 6, 103, 10.3390/medicines6040103